Detalhe da pesquisa
1.
Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
Gastric Cancer
; 17(1): 76-86, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23455716
2.
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Lancet Oncol
; 14(13): 1307-16, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24211163
3.
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Nat Genet
; 56(5): 809-818, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38671320
4.
Hazard assessment of antineoplastic drugs and metabolites using cytotoxicity and genotoxicity assays.
Mutat Res Genet Toxicol Environ Mutagen
; 892: 503704, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37973299
5.
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy.
Clinics (Sao Paulo)
; 76: e3146, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34644735
6.
Detection of anti-cancer drugs and metabolites in the effluents from a large Brazilian cancer hospital and an evaluation of ecotoxicology.
Environ Pollut
; 268(Pt A): 115857, 2021 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33139101
7.
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy
Clinics
; 76: e3146, 2021. tab, graf
Artigo
Inglês
| LILACS | ID: biblio-1339696
8.
Activation of RNA-dependent protein kinase and nuclear factor-kB by regulatory RNA from lipopolysaccharide-stimulated macrophages: implications for cytokine production.
Eur J Pharmacol
; 450(1): 85-9, 2002 Aug 16.
Artigo
Inglês
| MEDLINE | ID: mdl-12176113
9.
Primary monophasic synovial sarcoma of the kidney: a case report and review of literature.
Clin Med Insights Oncol
; 7: 257-62, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-24137053
10.
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
J Clin Oncol
; 31(14): 1719-25, 2013 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-23569311